Characteristic | No. (range) |
---|---|
Cytologic CR/PR | 7/2 |
Marrow response CMR/PMR | 3/1 |
Hematologic improvement | |
HI-N | 6 |
HI-P | 9 |
HI-E | 5 |
Cytogenetic response (conventional) CR/PR | 6/0 |
FISH response (BM) CR/PR/not done | 4/1/1 |
FISH response (CD34, pB)CR/PR | 4/2 |
Mitochondrial mutations CR/PR | 2/1 |
Median survival | |
All patients | 9.5 months |
Responders vs. marrow response vs. nonresponders | 23 vs. 9 vs. 7 months |
Median number of cycles | 5(2–43) |
Median number of cycles to response | 2(1–9) |
Dose reduction vidaza | 9 |
75% | 5 |
50% | 4 |
Median dosage VPA mg/kg | 25 (14–41) |
Maximum VPA level (median)/μg/ml | 86 (58–122)a |
Median VPA level (median)/μg/ml | 68 (44–97)a |
Median time to VPA level >70 μg/ml | 4 weeksb |
Patients with significant VPA side effects leading to: | 13 |
Dose reduction/Treatment break/cessation VPA | 7/5/3 |